Skip to main content

Table 2 Treatment response

From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Before matching Anti-PD-1 plus
sorafenib (n = 58)
Anti-PD-1
alone (n = 82)
p value
ORR 13 22.4% 16 19.5% 0.68
DCR 40 69.0% 31 37.8% < 0.05
 CR 5 8.6% 4 4.9%  
 PR 8 13.8% 12 14.6%  
 SD 27 46.6% 15 18.3%  
After matching Anti-PD-1 plus
sorafenib (n = 58)
Anti-PD-1
alone (n = 42)
p value
ORR 13 22.4% 9 21.4% 0.91
DCR 40 69.0% 14 33.3% < 0.05
 CR 5 8.6% 3 7.1%  
 PR 8 13.8% 6 14.3%  
 SD 27 46.6% 5 11.9%  
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease-control rate